Deutschland erlässt erste Sonderzulassungen für Corona-Selbsttests web.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from web.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 22, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a collaboration to create an at-home rapid test for SARS-CoV-2 using a BD antigen test and the Scanwell Health mobile app.
As part of the collaboration, BD plans to produce a lateral flow antigen test and pair it with the Scanwell Health mobile app. The app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample and use the mobile device s camera to analyze and interpret results. The test result will be displayed onscreen, and the companies are also planning to develop functionality to assist in automated reporting to public health agencies. This approach is intended to provide an efficient and scalable rapid antigen home testing solution.
COVID Test Results in 15min with New At-Home Test Service from Ready
COVID Test Results in 15min with New At-Home Test Service from Ready
Ready, an on-demand healthcare service, today announces in-home rapid COVID-19 testing with results in 15 minutes or less. The rapid test can be run from start to finish in the home, increasing the access to widespread testing outside of healthcare facilities. This testing capability not only reduces potential exposure at hospitals or testing sites, but also provides patients with fast and convenient results.
Why Readys COVID Test is Different Ready sends a healthcare professional with the appropriate personal protective equipment directly to a patients home or office – no lines, no increased risk of exposure “ just fast, private testing.
Taiwan develops microfluidic platform for rapid screening of diseases
Taiwan develops microfluidic platform for rapid screening of diseases 18 January 2021 | News Personalized Antibiotic Screening Platform fAST automates both genotype and phenotype detections to identify bacteria within 1.5 hours and finish the multiple antibiotics combination test within 5 hours
Photo Credit: PRNewswire
Taiwan s Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the health and well-being of patients.
Global research shows that 50% usage of antibiotics is inappropriate, and empirical treatment is one of the main causes. Empirical treatment usually gives 2~3 antibiotics at the same time to suppress unknown bacteria. However, no medical device currently in the market is able to conduct an antibiotics combination test to either confirm or predict if a combina